Why is EVE.SW stock moving pre-market today?

EVE.SW stock is up pre-market by **+9.56%** on 10 Feb 2026 due to thin liquidity and positioning ahead of the company’s earnings report on 20 Feb 2026, which traders expect could provide new guidance or clinical updates.

What are the main valuation metrics for EVE.SW stock?

Key metrics: **price CHF 0.85**, **EPS -0.12**, **PE -7.07**, **price-to-book 0.98**, **cash per share CHF 0.87**, and market cap **CHF 6,115,396.00**, reflecting a small-cap biotech with negative earnings.

What is Meyka AI’s forecast for EVE.SW stock?

Meyka AI's forecast model projects a yearly price of **CHF 2.33** compared with current **CHF 0.848**, implying a model-based upside of **+174.66%**. Forecasts are model-based projections and not guarantees.

How should investors manage risk with EVE.SW stock?

Manage risk with small position sizes, strict stop-losses, and monitor volume—today’s volume **278.00** is well below the **6,163.00** average. Expect high volatility around the 20 Feb 2026 earnings release.

CH Stocks

EVE.SW EvoNext S.A. (SIX) pre-market +9.56% to CHF 0.85 Feb 2026: earnings in focus

ByDanny Kontos February 10, 2026February 10, 2026

The EVE.SW stock is a pre-market top gainer on 10 Feb 2026, rising +9.56% to CHF 0.85 after early trades showed buying interest ahead of a scheduled earnings release. EvoNext Holdings S.A. (EVE.SW) trades on the SIX in Switzerland and closed the prior session at CHF 0.77. Volume is thin at 278 shares versus an average of 6,163, so moves can be amplified. Investors are watching the company’s upcoming earnings date on 20 Feb 2026 for guidance and potential catalysts in the biotechnology healthcare sector.